Icon Wealth Advisors LLC Acquires 289,144 Shares of Sanofi (NASDAQ:SNY)

Icon Wealth Advisors LLC grew its position in Sanofi (NASDAQ:SNY - Free Report) by 7,954.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 292,779 shares of the company's stock after buying an additional 289,144 shares during the period. Sanofi makes up about 0.6% of Icon Wealth Advisors LLC's investment portfolio, making the stock its 19th largest holding. Icon Wealth Advisors LLC's holdings in Sanofi were worth $16,873,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SNY. POM Investment Strategies LLC purchased a new position in Sanofi in the 2nd quarter worth about $25,000. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi during the third quarter valued at approximately $29,000. Concord Wealth Partners lifted its position in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after purchasing an additional 363 shares during the period. Arrow Financial Corp purchased a new stake in Sanofi in the second quarter worth approximately $35,000. Finally, Fortitude Family Office LLC grew its position in Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock worth $43,000 after purchasing an additional 659 shares during the period. Institutional investors own 10.04% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. StockNews.com downgraded Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 7th. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, July 26th. Finally, Citigroup upgraded Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.50.

Sanofi Price Performance

SNY stock traded up $0.30 during mid-day trading on Friday, hitting $48.28. The company had a trading volume of 3,549,361 shares, compared to its average volume of 2,051,022. The company has a 50-day moving average price of $53.88 and a 200 day moving average price of $52.16. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a market capitalization of $122.53 billion, a price-to-earnings ratio of 24.48, a P/E/G ratio of 1.22 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the previous year, the business earned $2.55 earnings per share. The firm's revenue for the quarter was up 12.3% on a year-over-year basis. On average, research analysts anticipate that Sanofi will post 4.29 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.